Skip to content
10-Q

Quarterly Report

PMV PHARMACEUTICALS, INC. PMVP

0000950170-24-093343

← back to feed
Filed
Aug 8, 2024 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q2 2024 · Aug 7, 2024 51.52M sh
Cash And Equivalents Q2 2024 · Jun 30, 2024 $48.53M
Cash And Equivalents Q2 2024 · Dec 31, 2023 $37.71M
Current Liabilities Q2 2024 · Jun 30, 2024 $11.39M
Current Liabilities Q2 2024 · Dec 31, 2023 $14.03M
Total Liabilities Q2 2024 · Jun 30, 2024 $23.22M
Total Liabilities Q2 2024 · Dec 31, 2023 $26.46M
Current Assets Q2 2024 · Jun 30, 2024 $218.79M
Current Assets Q2 2024 · Dec 31, 2023 $207.41M
Total Assets Q2 2024 · Jun 30, 2024 $237.54M
Total Assets Q2 2024 · Dec 31, 2023 $252.15M
Shares Diluted Q2 2024 · Jun 30, 2023 45.81M sh
Shares Diluted Q2 2024 · Jun 30, 2023 45.79M sh
Capex Q2 2024 · Jun 30, 2023 $721K
Operating Cash Flow Q2 2024 · Jun 30, 2023 −$27.91M
Stockholders Equity Q2 2024 · Jun 30, 2023 $217.81M
Stockholders Equity Q2 2024 · Mar 31, 2023 $230.17M
Stockholders Equity Q2 2024 · Dec 31, 2022 $246.03M
Eps Diluted Q2 2024 · Jun 30, 2023 −$0.38
Eps Diluted Q2 2024 · Jun 30, 2023 −$0.80
Eps Basic Q2 2024 · Jun 30, 2023 −$0.38
Eps Basic Q2 2024 · Jun 30, 2023 −$0.80
Sga Expense Q2 2024 · Jun 30, 2023 $6.28M
Sga Expense Q2 2024 · Jun 30, 2023 $12.69M
Rd Expense Q2 2024 · Jun 30, 2023 $13.84M
Rd Expense Q2 2024 · Jun 30, 2023 $28.92M
Net Income Q2 2024 · Jun 30, 2023 −$17.44M
Net Income Q2 2024 · Jun 30, 2023 −$36.56M
Net Income Q2 2024 · Mar 31, 2023 −$19.13M
Operating Income Q2 2024 · Jun 30, 2023 −$20.12M
Operating Income Q2 2024 · Jun 30, 2023 −$41.6M